SGLT2 inhibitors appear beneficial in advanced kidney disease, too

Reuters Health - 27/11/2020 - A post-hoc subgroup analysis of the CREDENCE study found that treatment with canagliflozin slowed kidney-function decline in patients with advanced diabetic kidney disease and also reduced the risk of kidney failure and heart problems. Based on the CREDENCE trial, the U.S. Food and Drug Administration approved the SGLT2 inhibitor for prevention of kidney failure among patients with type-2 diabetes with estimated glomerular filtration rate (eGFR) >30 mL/min per 1.73 m2. A lingering question is whether the drug is similarly beneficial in patients with a lower eGFR. To investigate, Dr. George Bakris of the University of Chicago Medicine and the CREDENCE trialists did a post-hoc efficacy and safety analysis of canagliflozin among the 174 trial participants who had eGFR <30 mL/min/1.73 m2 at randomization in comparison to those with eGFR at or above 30 mL/min/1.73 m2. During the 130-week follow-up period, canagliflozin ap...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 27 November, 20205 December, 2020